header logo image


Page 833«..1020..832833834835..840850..»

How maternal Zika infection results in newborn microcephaly – Baylor College of Medicine News

November 15th, 2019 8:45 pm

The current study was initiated when a patient presented with a small brain size at birth and severe abnormalities in brain structures at the Baylor Hopkins Center for Mendelian Genomics (CMG), a center directed by Dr. Jim Lupski, professor of pediatrics, molecular and human genetics at Baylor College of Medicine and attending physician at Texas Childrens Hospital, said Dr. Hugo J. Bellen, professor at Baylor, investigator at the Howard Hughes Medical Institute and Jan and Dan Duncan Neurological Research Institute at Texas Childrens Hospital.

This patient and others in a cohort at CMG had not been infected by Zika virus in utero. They had a genetic defect that caused microcephaly. CMG scientists determined that the ANKLE2 gene was associated with the condition. Interestingly, a few years back the Bellen lab had discovered in the fruit fly model that ANKLE2 gene was associated with neurodevelopmental disorders. Knowing that Zika virus infection in utero can cause microcephaly in newborns, the team explored the possibility that Zika virus was mediating its effects in the brain via ANKLE2.

In a subsequent fruit fly study, the researchers demonstrated that overexpression of Zika protein NS4A causes microcephaly in the flies by inhibiting the function of ANKLE2, a cell cycle regulator that acts by suppressing the activity of VRK1 protein.

Since very little is known about the role of ANKLE2 or VRK1 in brain development, Bellen and his colleagues applied a multidisciplinary approach to tease apart the exact mechanism underlying ANKLE2-associated microcephaly.

The team found that fruit fly larvae with mutations in ANKLE2 gene had small brains with dramatically fewer neuroblasts brain cell precursors and could not survive into adulthood. Experimental expression of the normal human version of ANKLE2 gene in mutant larvae restored all the defects, establishing the loss of Ankle2 function as the underlying cause.

To understand why ANKLE2 mutants have fewer neuroblasts and significantly smaller brains, we probed deeper into asymmetric cell divisions, a fundamental process that produces and maintains neuroblasts, also called neural stem cells, in the developing brains of flies and humans, said first author Dr. Nichole Link, postdoctoral associate in the Bellen lab.

Asymmetric cell division is an exquisitely regulated process by which neuroblasts produce two different cell types. One is a copy of the neuroblast and the other is a cell programmed to become a different type of cell, such as a neuron or glia.

Proper asymmetric distribution and division of these cells is crucial to normal brain development, as they need to generate a correct number of neurons, produce diverse neuronal lineages and replenish the pool of neuroblasts for further rounds of division.

When flies had reduced levels of Ankle2, key proteins, such as Par complex proteins and Miranda, were misplaced in the neuroblasts of Ankle2 larvae. Moreover, live imaging analysis of these neuroblasts showed many obvious signs of defective or incomplete cell divisions. These observations indicated that Ankle2 is a critical regulator of asymmetric cell divisions, said Link.

Further analyses revealed more details about how Ankle2 regulates asymmetric neuroblast division. They found that Ankle2 protein interacts with VRK1 kinases, and that Ankle2 mutants alter this interaction in ways that disrupt asymmetric cell division.

Linking our findings to Zika virusassociated microcephaly, we found that expressing Zika virus protein NS4A in flies caused microcephaly by hijacking the Ankle2/VRK1 regulation of asymmetric neuroblast divisions. This offers an explanation to why the severe microcephaly observed in patients with defects in the ANKLE2 and VRK1 genes is strikingly similar to that of infants with in utero Zika virus infection, Link said.

For decades, researchers have been unsuccessful in finding experimental evidence between defects in asymmetric cell divisions and microcephaly in vertebrate models. The current work makes a giant leap in that direction and provides strong evidence that links a single evolutionarily conserved Ankle2/VRK1 pathway as a regulator of asymmetric division of neuroblasts and microcephaly, Bellen said. Moreover, it shows that irrespective of the nature of the initial triggering event, whether it is a Zika virus infection or congenital mutations, the microcephaly converges on the disruption of Ankle2 and VRK1, making them promising drug targets.

Another important takeaway from this work is that studying a rare disorder (which refers to those resulting from rare disease-causing variations in ANKLE2 or VRK1 genes) originally observed in a single patient can lead to valuable mechanistic insights and open up exciting therapeutic possibilities to solve common human genetic disorders and viral infections.

Others who contributed in this study are Hyunglok Chung, Angad Jolly, Marjorie Withers, Burak Tepe, Benjamin R. Arenkiel, Priya S. Shah, Nevan J. Krogan, Hatip Aydin, Bilgen B. Geckinli, Tulay Tos, Sedat Isikay, Beyhan Tuysuz, Ganesh H. Mochida, Ajay X. Thomas, Robin D. Clark and Ghayda M. Mirzaa. They are affiliated to one or more of the institutions: Baylor College of Medicine, Texas Childrens Hospital and the Jan and Dan Duncan Neurological Research Institute in Houston, TX; University of California at Davis and San Francisco; Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Dr. Sami Ulus Research and Training Hospital of Women's and Children's Health and Diseases, Ankara, Turkey; Boston Childrens Hospital; Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA; Loma Linda University Medical Center, Loma Linda, CA; University of Washington, Seattle, WA; and Seattle Children's Research Institute, Seattle, WA.

The study was funded by the National Institutes of Healths F32NS092270, NIH/NINDS R35NS105078, NIH U54NS093793, NIH R24OD022005, NIH/NINDS K08NS092898, Howard Hughes Medical Institute (HHMI), Medical Research Fellowship, Jordans Guardian Angels, a jointly funded NHGRI and NHLBI grant to the Baylor-Hopkins Center for Mendelian Genomics (UM1 HG006542) and the Huffington Foundation.

Go here to read the rest:
How maternal Zika infection results in newborn microcephaly - Baylor College of Medicine News

Read More...

Kadimastem to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv,…

November 15th, 2019 8:44 pm

NESS ZIONA, Israel, Nov. 11, 2019 /PRNewswire/ --Kadimastem Ltd.(TASE: KDST),a clinical stage cell therapy company, today announced that it will present the interim results of Cohort A of its ongoing Phase 1/2a Clinical Trial in ALS (as published in Company's press release) at the 7th International Stem Cell Meeting, to be held on November 12-13 at the Dan Panorama Hotel in Tel Aviv, Israel.

The International Stem Cell Meeting, hosted by the Israel Stem Cell Society, is a highly reputed conference, participated by international world leaders in stem cell research.

Presentation Details:

Title: "FIRST IN HUMAN CLINICAL TRIALS WITH HUMAN ASTROCYTES AS A NOVEL CELL THERAPY FOR THE TREATMENT OF ALS"

Session:ONGOING CLINICAL TRIALS WITH CELL THERAPY

Presenter:Arik Hasson, PhD, Executive VP, Research and Development, Kadimastem

Date:Wednesday, November 13, 2019

Time:1:50 pm Israel

Location: Dan Panorama Hotel, Tel Aviv, Israel

Rami Epstein, CEO of Kadimastem, stated: "We are pleased to share these results with global leaders in the cell therapy and stem cells industry,demonstrating the potential of AstroRx, our astrocyte-based cell therapy product,to bring treatment to ALS patients, and possibly other neurodegenerative diseases. We look forward to further share data of this ongoing trial, with final results of cohort A expected by year-end 2019and results of cohort B expected in Q3, 2020."

About the Phase 1/2a ALS Clinical Trial

The Phase 1/2a trial is an open label, dose escalating clinical study to evaluate the safety, tolerability and preliminary efficacy of AstroRxcells in patients with ALS. The trial is expected to include 21 patients and is being conducted at the Hadassah Medical Center, Jerusalem, Israel. The primary endpoints of the trial are safety evaluation and tolerability of a single administration of allogeneic astrocytes derived from human Embryonic Stem Cells (hESC), administered in escalating low, medium and high doses (100x106, 250x106, and 500x106 cells, respectively). The medium dose will also be administered in 2 consecutive injections separated by an interval of ~60 days. Secondary end points include efficacy evaluation and measurements. Treatment is administered in addition to the appropriate standard-of-care.

About AstroRx

AstroRx is a clinical grade cell therapy product developed and manufactured by Kadimastem in its GMP-compliant facility, containing functional healthy astrocytes (nervous system support cells) derived from human Embryonic Stem Cells (hESC) that aim to protect diseased motor neurons through several mechanisms of action. The Company's technology enables the injection of AstroRxcells into the spinal cord fluid of patients suffering from Amyotrophic Lateral Sclerosis (ALS) with the goal of supporting the malfunctioning cells in the brain and spinal cord, in order to slow the progression of the disease and improve patients' quality of life and life expectancy. AstroRxhas been shown to be safe and effective in preclinical studies. AstroRxhas been granted orphan drug designation by the FDA.

About ALS

Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive fatal neurodegenerative disease causing disfunction in the upper and lower motor nerves that control muscle function. ALS leads to muscle weakness, loss of motor function, paralysis, breathing problems, and eventually death. The average life expectancy of ALS patients is 2-5 years. According to the ALS Therapy Development Institute, it is estimated that there are approximately 450,000 ALS patients worldwide of which 30,000 reside in the US. According to the ALS Foundation for Life, the annual average healthcare costs of an ALS patient in the US are estimated at US$ 200,000. Thus, the annual healthcare costs of ALS patients in the US alone amount to US$ 6 Billion.

About Kadimastem

Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic proprietary cell products based on its platform technology for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into clinical grade functional cells. AstroRx, the Company's lead program, is a clinical-grade astrocyte cell therapy for the treatment of ALS, currently undergoing a Phase 1/2a clinical trial. In addition, preclinical trials are ongoing with the Company's IsletRx pancreatic functional islet cells for the treatment of insulin dependent diabetes. Kadimastem was founded by Prof. Michel Revel, CSO of the Companyand Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Prof. Revel received the Israel Prize for the invention and development of Rebif, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

Company Contacts:Yossi Nizhar, CFO y.nizhar@kadimastem.com+972-73-797-1613

Investor and Media Contact:Meirav Gomeh-Bauermeirav@bauerg.com+972-54-476-4979

Global Media Contact:Dasy (Hadas) MandelDirector of Business Development, Kadimastemd.mandel@kadimastem.com+972-73-797-1613

SOURCE Kadimastem

https://www.kadimastem.com/

Read more:
Kadimastem to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv,...

Read More...

More Ways of Information Sharing Found in Living Things – Discovery Institute

November 15th, 2019 8:44 pm

Sharing of information is not evolution. Its like sharing library books instead of writing new ones. Biologists are continuing to uncover ways that living things pass around what they know. This is not good for Darwinism, which requires new information to arise by chance.

Science Daily uses the analogy of fishing with rod and reel to illustrate what bacteria do to acquire information they need.

A new study from Indiana University has revealed a previously unknown role a protein plays in helping bacteria reel in DNA in their environment like a fisherman pulling up a catch from the ocean.

The discovery was made possible by a new imaging method invented at IU that let scientists see for the first time how bacteria use their long and mobile appendages called pili to bind to, or harpoon, DNA in the environment. The new study, reported Oct. 18 in the journal PLOS Genetics, focuses on how they reel their catch back in. [Emphasis added.]

Pili (singular, pilus) are tiny extensions from the cell membrane that grow out and then retract. Why should a bacterium invent a way to defeat antibiotics when it can fish for it? The paper indicates two issues for ID vs Darwinism: (1) information is shared, and (2) molecular motors do the work.

Almost all bacterial species use thin surface appendages called pili to interact with their environments. These structures are critical for the virulence of many pathogens and represent one major way that bacteria share DNA with one another, which contributes to the spread of antibiotic resistance. To carry out their function, pili dynamically extend and retract from the bacterial surface. Here, we show that retraction of pili in some systems is determined by the combined activity of two motor ATPase [i.e., ATP-spending] proteins.

This is a far cry from claims by Darwinians decades ago that the rise of antibiotic resistance represents Darwinian evolution in action before our eyes.

The promise of making your own household goods by 3-D printing them hasnt quite arrived, but in theory, you could make a complex object of any shape, like a car part or tool, on your 3-D printer if you had the code for it. A recent paper in PNAS suggests that something similar happens in yeast. In this case, a prokaryote shares information with a eukaryote. Carla and Paula Gonalves found a way that eukaryotic yeasts which lost the code for vitamin B1 can retrieve it from bacteria and make their own again.

Food is the only source of the essential vitamin B1 for humans, but many microorganisms such as yeast and bacteria can synthetize it themselves. Here we report on a group of yeasts that have lost part of the vitamin B1 biosynthetic pathway in the past but have managed to rebuild it by capturing multiple genes from bacteria through horizontal gene transfer (HGT). We show a mosaic pathway composed of yeast and bacterial genes working coordinately to accomplish the synthesis of an essential nutrient. This involved adaptation of the bacterial genes to the very different expression rules in their new environment using several different mechanisms. Our results endorse HGT as an important mechanism for evolutionary adaptation in eukaryotes.

The authors can call it evolutionary adaptation to please the censors, but its really information sharing. Nothing evolved. The yeast didnt re-invent the vitamin B1 synthesis pathway; they lost it (as Behe would say, they devolved), and so they borrowed genetic instructions from bacteria to get back to where they used to be. The authors very few instances of the words evolved and evolution in the paper seem superfluous to any serious consideration of causation or explanation.

Picture information-sharing tunnels at the nanometer scale. These would be way too small to see, so it would require indirect imaging techniques to observe them in action. A team of scientists possibly uncovered a novel mechanism in mammalian inter-cellular cytoplasmic transfer and communication between mammalian cells. Its just a preprint in bioRxiv, so the story will need further verification, but if observations confirm what the scientists think they are seeing, tunneling nanotubes and fine and often branching cell projections pass organellar cargo from cell to cell. In their experiments, healthy cells were found pumping material to malignant cells.

Discrete, rapid and highly localized transfer events, evidenced against a role for shed vesicles. Transfer coincided with rapid retraction of the cell-projections, suggesting a hydrodynamic mechanism. Increased hydrodynamic pressure in retracting cell-projections normally returns cytoplasm to the cell body. We hypothesize cell-projection pumping (CPP), where cytoplasm in retracting cell-projections partially equilibrates into adjacent recipient cells via micro-fusions that form temporary inter-cellular cytoplasmic continuities.

Cells can not only use protrusions to pump but also to poke neighboring malignant cells. In Nature, Kendall Powell discusses the growing realization among microbiologists that cells can evict, kill or cannibalize less-fit rivals. To do that, cells must have methods of sensing who is good and who is bad, and cooperating as a team. The burgeoning field of cell competition uses the Darwinian lingo of fitness and competition, but this really sounds more like a case of what Marcos Eberlin calls Foresight: the ability to foresee problems and have mechanisms in advance to deal with them.

The best-known case of genetic information sharing is, of course, sexual reproduction. Humans are all one species, Homo sapiens, so everyone is genetically compatible. But what about alleged human ancestors with other species names? Can they share genes?

One of the most astonishing developments in paleoanthropology in the last two decades was the discovery of Neanderthal DNA within us. As the myth of Neanderthals being other members of Homo began to crumble, first it was small bits of Neanderthal DNA, then more and larger segments. Next, Denisovan DNA was found mixed in with Neanderthal and living human genomes. Now, New Scientist reports, Long strand of DNA from Neanderthals found in people from Melanesia. Some paleoanthropologists are thinking that all three groups were genetically compatible with Homo erectus and other archaic humans.

Michael Marshall suggests that theres function, not just randomness, in these cases of genetic mixing:

The archaics have contributed to the success of humans that left Africa, says Eichler. Neanderthals and Denisovans lived in Europe and Asia for hundreds of thousands of years before modern humans emerged from Africa, so they would have evolved adaptations to the different climates, foods and diseases. These useful genes were kind of test-run in our precursors, says Eichler. Theyre basically borrowed.

Predictably, Marshall remains Darwinian in his thesis, but its not necessary to assume that the Africans invented their adaptations by chance mutations and natural selection. ID research could approach the same observations with Foresight in mind: humans have always had engineered mechanisms that could adapt to a wide variety of circumstances. If African meets European and they get twinkles in their eyes, why, theres a quick way to share their library books.

So, scientists continue to find ways that organisms share pre-existing genetic information. Old Darwinian paradigms continue to fall as observations reveal useful information passing through tunneling nanotubes, pili, and secretion systems from cell to cell. Organisms wouldnt borrow useless junk. If they are found reeling in DNA or passing it through secret passageways, it must be a good read.

Photo: Library shelves, bySusan YinviaUnsplash.

Visit link:
More Ways of Information Sharing Found in Living Things - Discovery Institute

Read More...

Is Protein Therapeutic Market Trapped Between Growth Expectations and Uncertainty? – Daily Market Headlines

November 15th, 2019 8:44 pm

AMA recently published a detailed study of over 180+ pages in its repository on Protein Therapeutic market covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are Merck KGaA (Germany),Thermo Fisher Scientific Inc. (United States),Becton, Dickinson & Company (United States),Agilent Technologies, Inc. (United States),QIAGEN N.V. (Netherlands),Takara Bio Inc. (Japan) ,Lonza Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (United States),GenScript Biotech Corporation (China) ,Lucigen Corporation (United States),Synthetic Genomics Inc. (United States),Promega Corporation (United States),New England Biolabs, Inc. (United States) ,Sengenics (Singapore)

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/85549-global-protein-therapeutic-market

Protein Therapeutic refers to proteins which are engineered in the laboratory so it can be used in pharmaceutical use. These are an important class of drugs which serves patient in need of novel therapies. Protein Therapeutics treat a wide array of clinical indication which includes cancer, infectious diseases, genetic disorder and metabolic disorder.

Market Segmentation:by Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), Application (Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Hormonal Disorders, Genetic Disorders, Others), End User (Pharmaceutical and Biotechnology Companies, Healthcare service providers, Research Organizations and Academic Research Institutes, Other)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/85549-global-protein-therapeutic-market

Whats Trending in Market:Technological Advancements Such As Mass Spectrometry, Advances In Molecular Genetics, And Progress In Production Technologies

Growth Drivers:

Increase In Prevalence Of Chronic Diseases

Government Initiative to Improve The Healthcare Services

Rising Demand For High-Quality Recombinant Therapeutics

Rising Research Activities On Protein Therapeutics

Restraints:

High Costs Associated With Therapeutic Proteins

Binding Government Regulations For Protein Therapeutics

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/85549-global-protein-therapeutic-market

Country level Break-up includes:North America (United States, Canada and Mexico)Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Strategic Points Covered in Table of Content of Global Protein Therapeutic Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Protein Therapeutic market

Chapter 2: Exclusive Summary the basic information of the Protein Therapeutic Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Protein Therapeutic

Chapter 4: Presenting the Protein Therapeutic Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Protein Therapeutic market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=85549

Contact Us:CRAIG FRANCIS (PR & Marketing Manager)sales@advancemarketanalytics.com

Ph: +1 (206) 317 1218

Continue reading here:
Is Protein Therapeutic Market Trapped Between Growth Expectations and Uncertainty? - Daily Market Headlines

Read More...

KWASU advocates increased agric production to meet global population by 2020 – NIGERIAN TRIBUNE

November 15th, 2019 8:44 pm

A professor of molecular genetics and plant breeding in the department of crop production, College of Agriculture, Kwara State University (KWASU), Olawale Aliyu, had said that agricultural production must increase by 80 per cent to meet world population of 7.7 billion to 10 billion by 2020.

Delivering sixth inaugural lecture of the university, titled, Decoding the secret of life: Plant, sex and sustainable food production, Professor Aliyu said that innovative breeding technologies for improving existing crops for better adaptation, among other measures, should be embarked upon to achieve the task ahead.

The KWASU don, who charged the federal government to give urgent priority to research by providing resources for functional laboratories, said that such labs should be equipped with modern technologies.

Theres the urgent need for the federal government to give priority to research by providing resources for functional laboratories, equipped with modern technologies and training of manpower that will carry out advanced research in agricultural production for sustainable food security.

The government should also strengthen the capacity of Nigerian scientists to embark on genetic engineering of our major food crops in addition to the conventional system being used.

ALSO READ:Changing outdated curriculum

The government should put in place monitoring mechanism to prevent the influx of GMO crops into the country because of its effect on the biodiversity of our plant and animal resources. Our national breeding programmes on cereals and grain legumes should consider integrating the use of apomixis technology for hybrid seed development because of its potential to revolutionize agriculture, he said.

Professor Aliyu, who said that advances in genetic research are moving at jet speed, added that there is an urgent need to review training curriculum in plant breeding and genetics for students in Nigerian universities to reflect current realities.

The KWASU don also said that cashew has the potential to transform the economy of Kwara state, adding that the sector should be properly organized and the industry is supported.

There is an urgent need for the Kwara state government to develop a 10-year strategic plan for the transformation of an agricultural commodity, especially cashew, where it has a competitive advantage. I am aware that the state government initiated a farmer-ownership cashew project that targeted 5,000 hectares per local government area with processing plants in each senatorial district in 2005, but this project was aborted before takeoff. The current administration can revisit this as part of the effort to lay a solid foundation for a sustainable economy of our dear state. The state government should partner with the federal government to stop the illegal shipment of nuts across porous borders to neighbouring countries, he said.

Read the original:
KWASU advocates increased agric production to meet global population by 2020 - NIGERIAN TRIBUNE

Read More...

Opinion: Personalized Medicine Is The Solution To Modern Cancer Treatment – BioSpace

November 15th, 2019 8:43 pm

The following is an opinion article written by Laura Towart, CEO and founder of My Personal Therapeutics, a London based digital health company offering advanced personalized cancer therapeutics. Their Personal Discovery Process uses fruit fly avatars to genetically mimic a patients cancer to identify drug combinations against the specific cancer. You can learn more about the company by reading this BioSpace article or going to their website.

The medical sector is getting carried away with a one size fits all approach to cancer treatment.

A cancer diagnosis simply means the patient has a condition that propagates abnormal cells within their body. This conditions underlying cause and characteristics will naturally differ between patients, but oncologists tend to prescribe a shockingly consistent course of treatment: anti-cancer medication and a course of chemotherapy. An estimated 1,735,350 Americans were diagnosed with cancer in 2018, but 1.7 million people cant all be the same.

Consumers have come to expect high levels of personalization from their smartphones, home designs, and online shopping experiences, and end up enjoying these things more as a result. They also deserve a personalized approach in cancer treatment that considers their unique genetic traits and the latest medical research this methodology stands a significantly increased chance of pushing back against the disease.

Personalized medicine tailors medical treatment to each patients unique characteristics

Factoring in conventional data points about the individual patient is just the start: their medical history, which country theyre from, and how physically active they are certainly constitute useful markers to guide treatment. But now its possible to go several layers beyond that and achieve a fuller picture by sampling the patients DNA, gaining a view into the genetic recipe that makes them who they are.

When scientists sequenced the complete human genome in 2003, it unlocked a new era of medical possibilities. There are approximately 3 billion pairs of chemical building blocks (called bases) in the human genome; the order in which they appear reveals the genetic information that each segment of DNA carries. In other words, medical researchers had developed a kind of Rosetta Stone for human genetic information. This forms the underpinning for personalized medicine today.

Medical professionals working in this arena can enhance their understanding of how someones unique molecular and genetic profile might leave them vulnerable to certain diseases or conditions, whether that information was already medically known or not. Where previous approaches to cancer treatment presented oncologists with a set of assumed best practices, personalized medicine gives them a figurative telescope to explore many possible treatments and determine one with an optimal outcome.

Fruit flies can be a powerful weapon for personalized medicine professionals

Medical researchers can use fruit flies to see the future. At the surface level, these kitchen pests have basically nothing to do with human biology, but they actually share up to 75 percent of the genes associated with human disease. Theyre furthermore one of the most genetically malleable organisms out there, capable of handling 15 mutations or more.

They present us with a valuable analog to see how a human body will metabolize and distribute a drug. A tumor generated in the fly gut can resemble a human colorectal tumor. As its inside the body (instead of on a cancer cell culture plate), it actually interacts with other organs in a long-range communication process. In other words, medical researchers like the ones at Mount Sinais Center for Personalised Cancer Therapeutics (CPCT) or at partner company My Personal Therapeutics can direct a genetically similar tumor to grow inside of a fruit fly, then experiment on it to see what kind of treatment works. Because fruit fly lifespans are very short, its easy to do this at a large scale and get meaningful results very quickly.

Personalized medicine will change the way we think about, identify, and manage cancer

Youve probably heard the term big data before in reference to business and internet technology. When the medical world collects highly precise data about individual patients at scale, it effectively lays the foundation for a comparative database that will make high-quality diagnoses quicker and more affordable in the future. In the long term, this will present doctors with trusted shortcuts for providing more accurate cancer treatment.

Imagine that personalized medicine has been the norm for 20 years and every physician has access to data that compares symptoms and treatments across all individuals. Doctors would only need to plug your vital statistics into a database and check them against your declared symptoms in order to see what worked for other people just like you. When I say just like you, I really mean it. This is the value of big data well eventually be able to segment out previous patients of all different demographics with deep specificity.

The future of cancer treatment is much like the future of medicine at large. Its going to depend on highly individualized approaches that harness all of a patients data, from their lifestyle to their genetic code. Genetic methodologies grant medical professionals access to a fuller picture of patient health than theyve ever had before. Its time to start using them on an individual basis in order to ensure high-quality outcomes for cancer patients.

You dont need to be a medical expert to know one size doesnt fit all.

Go here to see the original:
Opinion: Personalized Medicine Is The Solution To Modern Cancer Treatment - BioSpace

Read More...

A Revolution in the Creation of Scientific Workplaces – Scientific American

November 15th, 2019 8:43 pm

In todays hypercompetitive research environment, successful organizations know strategic workplace design is no longer a luxury. Historically, providing a private office and a large wet lab were enough to attract great talent and achieve expected results.

However, todays researchers are challenging the status quo as they seek creative ways to perform their work. These researchers are looking for workspaces that enable new levels of collaboration, creativity, flexibility and well-being. Convergent scientific workplace design is based on the widely recognized convergence research model that has been proven to break down traditional barriers of scientific discovery and pave the way toward improved recruitment, retention, productivity and innovation.

WHAT IS CONVERGENCE RESEARCH?

Scientific research is undergoing a transformational change. Highly specialized gene therapies now cure once incurable cancers. Personalized medicine and big data help doctors treat and prevent diseases better than ever before. The ever-advancing technologies behind these breakthroughs are driving a new paradigm of cutting-edge, integrated research across multiple fields and industries that have been historically distinct disciplines. Many have defined this shift as the convergence revolutionone that shares methods and ideas from chemists, mathematicians, economists, computer scientists, biologists, physicists, engineers and more to improve the lives of millionsif not billionsof people.

Many initiatives are underway to expand awareness and encourage more scientists to adopt the convergence model of research. The National Science Foundation (NSF) has identified convergence research as one of its 10 Big Ideas for the agency and is creating a solicitation process to encourage convergence in a subset of its research and center awards. The National Academies Government-University-Industry Research Roundtable and the National Academy of Sciences have held formal workshops on the topic.

WHY IS WORKPLACE DESIGN IMPORTANT?

In this convergence research model, the scientific workplace environment is more important. With so many disciplines sharing the same spaceall with different needs and ways of workingand more remote team members needing means to collaborate, it is important for institutions to understand the role facility design can play in its success or failure. When we talk about optimizing the workplace environment, we are ultimately talking about the researchers within. They are the factors that influence performance, innovation and retentionall of which are measures of success for a research institution.

The cost of unhappy researchers can be devastating. In a paper titled Innovation spaces: Workspace planning and innovation in U.S. university research centers, researchers Umut Toker and Denis Gray cite that over a period of 10 years, operating and maintenance costs of an organization remain around 8 percent, whereas human costs remain around 85-90 percent. It is much more advantageous for institutions to focus on long-term productivity, increased collaboration, and reduction of turnover to reduce cost rather than focusing on the short-term, operational and maintenance of the facility itself.

Sometimes it is seemingly more difficult to demonstrate how workplace planning can influence innovation in an organization. Toker and Grays study proved this correlation through data analysis that there is a significant relationship between workspace planning, consultations and innovation process outcomes, citing that university research centers featuring overall high configurational accessibility, shorter walking distances and intact territories exhibit higher face-to-face consultation rates, consultation network connectivity, and subjective/objective innovation process outcomes.

WHAT DESIGN STRATEGIES CAN IMPROVE RESEARCH OUTCOMES?

When renovating or creating a new research work environment, there are three important design strategies to consider that can ultimately affect research outcomes.

Collaboration

Far too often, scientists are separated from each other in formally arranged spaces, reflecting linear processes and static functionality, and status is reflected by size of internal real estate and the allocation of enclosed offices. The convergence research environment embraces new methodologies of working where multidisciplinary teams can come together away from their departmental homes. Through design, we can encourage informal social interactions and foster intentional collisions of people with diverse backgrounds and skill sets to catalyze innovation.

In order to foster social ties, workplaces should make it easier for people to interact and provide places where people are comfortable talking about things other than work. One tactic is to create social spaces at intersections where people are likely to bump into acquaintances with whom they may not regularly work. To enhance the impact of central social spaces, these informal collaboration areas should be highly visible, located along central circulation paths and within reasonable walking distances of key collaborators. In addition, these spaces should have amenities such as coffee, snacks, seating and comfortable standing gathering areas.

A study at the University of Michigan supports co-locating team members, finding that researchers who occupy the same building are 33 percent more likely to form new collaborations than researchers who occupy different buildings, and scientists who occupy the same floor are 57 percent more likely to form new collaborations than investigators who occupy different buildings.

Example: Johns Hopkins University Applied Physics Laboratory, Building 201, Laurel, MD

Johns Hopkins University Applied Physics Laboratory Building 201 is an interdisciplinary research facility that will provide flexible laboratory and office space in a highly collaborative, open workplace environment. The laboratories are organized in a shared facility plan, which features glass enclosures that promote more interaction. They are designed around a four-story daylit atrium in conjunction with generous, unassigned collaborative spaces offering researchers many options for focused, informal and group work activities. Cafs are on every floor, which promote greater interactions between researchers from different departments. When complete, there will be over 50 different collaboration environments and over 20 different laboratory environments suited to fit researchers needs.

Flexibility

The performance of researchers is optimized when they feel they have some control over the physical conditions they experience there. Permanent fixtures and traditional laboratory layouts were designed for the slower-moving research of the past. However, researchers today are more mobile, more agile and desire a workplace that can be quickly and easily optimized for their needs. Flexibility within laboratories includes a multitude of integrated design approaches, including flexible engineering systems, modularity of furniture and casework, and accessibility. Key to accommodating flexibility is designing spaces that can easily transform when new processes are realized or new breakthroughs are discovered.

There should be a fluid mix of wet and dry spaces in a convergence research laboratory. This level of flexibility is beneficial because researchers in a convergence model are just as likely to be doing wet bench work as they are to be doing prototypes, physical and virtual simulations, data informatics and data analysis. Having the wet bench in close proximity to dry labs (and write-up areas) allows researchers to move quickly from task to task, without having to leave their floor or building.

Flexibility is the physical expression of convergence research. If we expect researchers to think broadly outside of their particular domains of expertise, we need to provide them spaces to interact and work alongside a wide-ranging team from traditional wet bench scientists to anthropologists.

A universal bench layout is also advised to increase flexibility. Using a best practice in the health care field, an overhead service boom can support the flexibility of a bench layout, which serves power, data and lab gases. Task lighting can also move with the furniture to ensure a consistently high-quality visual experience regardless of physical location.

Example: CJ Blossom Park, Suwon, South Korea

The 1.2 million sf building consolidates CJ Corporations previously disparate pharmaceutical, biotechnology, and food products businesses into a single location, enabling it to create industry-defining product strategies and increase its global competitiveness. The design team tested and explored a multitude of bench layouts through the design phase A universal bench design changes the traditional 6 wide x 2.5 deep bench to 5 x 2.5 so it is non-directional and can be configured in parallel or perpendicular direction. These are used throughout the building for both instrumentation and desk activities and provides greater flexibility and encourages more open teaming spaces.

The universal benches are all on wheels, which enable users to configure benches in several different wayslinear, T shaped, U shaped, or L shapedbased on team, project and process. The universal bench can be used for both instrumentation and desk activities. This allows even greater flexibility to scale up or down instrumentation or headcount for a multitude of changing environments such as contractors or summer interns. This also eliminates the need of write-up space in the lab and encourages more open teaming spaces.

Wellness

Lastlyand possibly most importantlyis the focus on researcher wellness. There is an incredible body of work that proves the correlation between the design of the workplace and the quality of work done by the people in it. Gone are the days of researchers tolerating a workplace in the basement. Despite strict environmental requirements in many spaces, researchers nevertheless are expecting workplaces that deliver on their wellness needs. Research space needs to focus on human health through strategies such as natural light, soft seating and acoustics. Researcher comfort and satisfaction are crucial, as it can greatly influence recruiting and retention as discussed above.

Ample access to daylight has proven time and again its benefits in the workplace. In a laboratory setting, this may prove more difficult due to challenges like photosensitive materials handling and glare concerns. However, there are design strategies that can improve daylight access. Consider orienting seating perpendicular to exterior windows. Provide shading devices, particularly on south and west facing windows. Place light sensitive equipment in the center of the floorplate away from the exterior. Consider borrowing daylight into labs from write-up areas and offices.

Noise control has also proven critical to workplace wellness. This factor is often overlooked or is taken out of the design as a cost-saving measure, but it is highly important and should be seriously considered when designing a laboratory environment. Noise reduction strategies can include creating equipment rooms for loud, noisy equipment like minus 80 degree F freezers. Break down large, open labs by zoning into smaller spaces through glass walls, demountable walls, or floor-mounted equipment (like fume hoods). Finally, consider acoustics in ceiling and floor selection.

Example: Novartis-Penn Center for Advanced Cellular Therapies (CACT), Philadelphia

Located on Penn Medicines campus in Philadelphia amidst both clinical care and laboratory facilities, the 30,000 sf Center for Advanced Cellular Therapies (CACT) brings together Penn Medicines intellectual resources combined with pharmaceutical industry leader Novartis with the mutual goal of expediting the development of novel gene therapies for complex diseases of all kinds. To take advantage of the natural light and views, the processing cells are located on the perimeter using a double-wall construction design that provides the necessary isolation of the controlled environment. Additionally, to shield the material from ultraviolet rays, the design team installed polarized film on the windows for some of the most sensitive rooms in the facility so that, with a flick of a switch, the polarization is activated.

Convergence research is the future of science. It is not easy to bring together the strengths of many disciplines; however, it is necessary to help solve the incredibly complex challenges of today and tomorrow. Convergent scientific workplaces can be designed to promote collaboration, flexibility and wellnessall of which can lead to better research outcomes.

For more information on this topic, please see this white paper.

View original post here:
A Revolution in the Creation of Scientific Workplaces - Scientific American

Read More...

Personalized Medicine Market 2019| In-depth Analysis by Regions, Production and Consumption by Market Size, and Forecast to 2026 | Research Industry…

November 15th, 2019 8:43 pm

The Global Personalized Medicine Market (2019 2026) research offers a basic overview of the industry including definitions, applications, classifications, and market chain structure. Moreover, in the global Personalized Medicine Market report, the key product categories of the market are included. The report comparably demonstrates supportive data related to the dominant players in the market, for instance, product offerings, segmentation, revenue, and business synopsis. The global Personalized Medicine Market is as well analyzed on the basis of numerous regions. The firstly the report describes the market overview, cost structure, upstream, and technology. The second part describes the global Personalized Medicine market by key players, by application and type.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): http://researchindustry.us/report/personalized-medicine-market-ric/773699/request-sample

Competitive Analysis

The global Personalized Medicine market report wraps scope and product overview to define the key terms and offers comprehensive information about market dynamics to the readers. This is trailed by the regional outlook and segmental analysis. The report also consists of the facts and key values of the global Personalized Medicine market in terms of sales and volume, revenue and growth rate.

One of the important factors in the global Personalized Medicine market report is competitive analysis. The report covers all the key factors, such as product innovation, market strategies of the key players, market share, revenue generation, latest research and development, and market expert views.

The followingTopmanufacturersare assessed in this report:

Abbott LaboratoriesAgilent TechnologiesAmgenAstellas PharmaAstrazenecaBayer AGCelgene CorporationGlaxosmithkline PlcIlluminaJohnson & JohnsonLaboratory CorporationMerckNovartis AGRoche Holding AGSiemens AGTakeda Pharmaceutical Company Limited

Personalized Medicine Market Segmentation

For the better grasp insight of the market, this report has provided a detailed analysis of drivers restraints, and trends that dominate the present market scenario and also the future status of the global Personalized Medicine market during the projected period of 2018-2026.

Market Analysis by Product Type

Personalized Medicine DiagnosticsPersonalized Medical CarePersonalized Medicine TherapeuticsPersonalized Nutrition and Wellness

Market Analysis by End-User Application

OncologyCentral Nervous System (CNS)ImmunologyRespiratoryOther Applications

While classifying these segments, the expert team of analysts has listed the relative contribution of each segment for the growth of the global Personalized Medicine market. Detail information of segments is required to recognize the key trends influencing the global market for the Personalized Medicine.

Each segment of the market provides a piece of in-depth information on the qualitative and quantitative aspects of the market. While giving a brief idea about the revenue opportunities for all the segments, this report has also provided the value of absolute dollar opportunity for all the segments over the predicted period of 2018 2026.

Regional Analysis

The significant regions covered in the reports of the global Personalized Medicine market are North America, Europe, the Asia Pacific, South America, and the Middle East and Africa. The market information not only provides the market data of the five geographies as a whole, but it also provides you qualitative as well we qualitative information on country level bifurcation. Adding to that, economic, technological, cultural and social aspects along with the regulatory barriers are entirely analyzed to understand the thorough market scenario across different geographies.

The key highlight of the Research:

Key Questions Answered:

Get In Touch!

Navale ICON IT Park,

Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, Pune

Maharashtra 411041

phone +91-020-67320403

Email help@researchindustry.us

Original post:
Personalized Medicine Market 2019| In-depth Analysis by Regions, Production and Consumption by Market Size, and Forecast to 2026 | Research Industry...

Read More...

UC Davis leads in innovative gene editing research with NIH grants – The Aggie

November 15th, 2019 8:43 pm

Researchers strive to address societal health issues through gene editing

In October, three researchers at UC Davis were awarded a $1.5 million grant to fund their project which attempts to demonstrate the effectiveness of gene editing through use of CRISPR, a powerful technology that allows alteration of DNA sequences to change gene function.

This kind of design can help enhance personalized medicine, said R. Holland Cheng, a professor of molecular and cellular biology in the College of Biological Sciences. Specific patients with specific illnesses can be treated in specific ways.

Cheng, along with Kit Lam, a distinguished professor and chair of the Department of Biochemistry and Molecular Medicine in the School of Medicine, and David Segal, a professor in the Department of Biochemistry and Molecular Medicine, were awarded this highly competitive and sought-after grant from the National Institute of Health (NIH).

UC Davis is part of the NIHs Somatic Cell Genome Editing (SCGE) consortium which has awarded grants to 45 other research institutes across the nation so they can begin groundbreaking work on gene editing. Through this consortium, the NIH hopes to find an efficient and safe way to conduct gene editing. Research programs are investigating the best delivery mechanism as well as the most dynamic gene editing tool.

The major problem with gene editing currently is the inability of cells to be edited within a living organism. It has become fairly easy and efficient to edit genes in a cell culture outside of the body but extremely difficult to do the same processes inside the body. Cheng, Lam and Segal are focused on changing this.

The question is how to do it inside of an animal and eventually a human, Lam said.

They are answering this question by utilizing Chengs work in engineering a non-toxic nanoparticle that they hope can transport the gene editing tool CRISPR into the cells of a living organism. Cheng has been able to create a Hepatitis E viral nanoparticle (HEVNP) that when manipulated could be a delivery system for CRISPR. They plan to take this nanoparticle and encase CRISPR inside of it, producing a mechanism for delivery of CRISPR.

The Hepatitis E nanoparticle has the capacity to be a highly efficient way to deliver gene editing to cells in the body due to its unique nature. HEVNP is resistant to the gastric acid environment of the intestines and stomach, enabling it to survive once its entered the body. Given its resistant abilities, HEVNP can be taken orally, making it a useful form of medicine. If able to successfully get HEVNP to the target cells in the body and deploy CRISPR, gene editing abilities could drastically change.

The addition of a cell-type specific targeting ligand to the HEVNP would code the nanoparticle to deliver CRISPR to a specific cell. The abilities of this method to be precise and safe will determine its success.

With five years of funding from the NIH, these three researchers are eager to begin work on this project and see the strides that can be made in gene editing. They have impressive goals for this research, as it has the capacity to reshape medicine.

This will redefine precision medicine as currently there is broad medicine that can cause side effects to people and not be effective, yet by making it specialized it is becoming more precise and effective, Cheng said.

As more effective and safe tools to cure illnesses are being tested and created, the benefits to society could be expansive. With so much potential to help improve the health of society, the NIH is dedicated to coming to new solutions at a quick rate. All programs that received grants will be required to share and utilize the research occurring at other funded programs. The NIH is hoping to eliminate the private nature of research through enforcing the sharing of ideas, as scientists are often constrained by the institutions they work for. It is their hope that by having communication between the programs, positive results will arise faster.

I think this is great because scientists inherently want to work with each other but have real world concerns especially with money, Segal said.

The research results, when groundbreaking, can provide incredible monetary gains and credibility to the institutions that made the discovery. Ultimately, scientists collaborating with one another will serve society as people are able to benefit earlier from this innovative research.

We want the public to know that we are working in their best interest, Segal said.

The NIH grant is competitive and still the third research program to join the consortium at UC Davis. Innovation has never been more prevalent than in this field at UC Davis. With three different programs researching gene editing, UC Davis stands out as a hotspot for this field of research.

Written by: Alma Meckler-Pacheco science@theaggie.org

Go here to see the original:
UC Davis leads in innovative gene editing research with NIH grants - The Aggie

Read More...

Lifebit and Medley Genomics Partner to Deliver Streamlined Solution Supporting New Diagnostic and Therapeutic Discoveries – BioSpace

November 15th, 2019 8:43 pm

Researchers can now tap new disease discoveries using Medley Genomics HotNet2 at enterprise scale, over any system, across distributed data with Lifebit CloudOS

LONDON, UK - Nov 14, 2019 - Lifebit Biotech, a leading innovator in bioinformatics and cognitive software solutions, and Medley Genomics, a company focused on using advanced data analytics to support better diagnosis and treatment of complex diseases, announced today their partnership agreement. The Lifebit-Medley partnership aims at removing the barriers impeding progress in precision medicine where advanced biomedical analysis tools, like HotNet2, must be deployed over distributed and complex data to arrive at breakthrough insights.

Lifebit CEO, Dr Maria Chatzou Dunford, said, We are thrilled to announce our partnership with Medley Genomics, which allows us to bring advanced tools to the biomedical research community, advancing knowledge by powering the investigation of new diagnostic and therapeutic opportunities. Any company or researcher can now discover disease driver genes and novel pathways by utilising the high performance HotNet2 at enterprise scale and over distributed cohorts of patient data without needing to move the data.

Developed by Medley co-founder Dr Ben Raphael, HotNet2 assesses the complex heterogeneous genomic landscape across patient cohorts, including the long tail of disease relevant genes, by building significantly mutated gene subnetworks based on mutational frequencies and known interaction networks. Because HotNet2 comes with many dependencies, installation was complex without Lifebit CloudOS. To increase the power of analysis, experimental setups need to include as many samples as possible. Unless users have endless resources to spend on sequencing and data generation, they would need to combine disconnected data from various public and private sources, presenting a major obstacle to progress.

With Lifebit CloudOS, HotNet2 now runs over distributed data using federated capabilities, providing immediate access to infinite compute resources, said Dr Patrice Milos, Medley Genomics CEO. Increasingly our customers are applying HotNet2 to define subgroups within their patient disease cohorts and to reveal novel biological pathways. Our partnership with Lifebit enables us to reach countless more researchers across our shared communities helping them to simplify their work processes and ultimately bring important discoveries to patients faster.

By deploying HotNet2 with Lifebit CloudOS, analyses are seamlessly executed and distributed data is united through federated analysis - data is never transferred and security is assured. This is critical as analyses can run at sample-level within the users cohort or across different patient cohorts, without compromising the data by moving them outside their secure environment. Detailed reports can be generated at scale, including visualisations for each run, and instantly shared for true collaboration across teams. The HotNet2 solution is available to anyone via the Lifebit CloudOS Marketplace.

View pan-cancer HotNet analysis here.Try cloud-native HotNet2 here.

ABOUT LIFEBITLeading life sciences organisations are accelerating their research and discoveries with Lifebit. Lifebit CloudOS is the federated, integrated solution for fully FAIR omics and biomedical analysis, allowing anyone to streamline and scale analyses faster, cheaper, and securely in their own data environments. Lifebit AI-Engine has deep-learned the biology behind drug response and is helping pharmaceutical companies repurpose drugs, validate targets and optimise vaccines by reasoning about omics data like humans would. Headquartered in London, UK, Lifebits ecosystem of employees, partners, and customers spans 15 countries. Visit lifebit.aiLifebit press contact: pr@lifebit.ai

ABOUT MEDLEY GENOMICSMedley Genomics Inc., based in Providence, Rhode Island, US, provides cutting edge algorithms and software to deliver on the promise of individualization of therapy. The companys approaches provide deep insight into the heterogeneity of disease as well as defining unique disease mechanisms across disease cohorts. Applied first in oncology, these insights are necessary for optimizing targeted and combination therapies, personalized cancer vaccines and immunotherapies to effectively treat the total disease burden and offer hope of lasting cures for patients. Visit Medleygenomics.comMedley press contact: info@medleygenomics.com

See the article here:
Lifebit and Medley Genomics Partner to Deliver Streamlined Solution Supporting New Diagnostic and Therapeutic Discoveries - BioSpace

Read More...

Wearables and Healthcare: The 3 Companies Leading the Way – Nasdaq

November 15th, 2019 8:43 pm

Initially seen as a fashion accessory, smartwatches and fitness bands have now entered the healthcare ecosystem. By leveraging advanced technologies such as Artificial Intelligence (AI), Cloud, Machine Learning, Big Data and Analytics, these wrist-worn devices are becoming more sophisticated and relevant in the present day by providing actionable insights and prescriptive measures for end users. This has also ushered in technology giants such as Apple, Samsung and Google in the healthcare space.

Heres a look at the fast-growing wrist-wear market in the backdrop of the digital health space

The increasing focus on personalized care, early detection, and precision medicine along with rising health consciousness is driving the demand for healthcare-related wearables and applications. Asurveyby Accenture shows that the use of wearable devices by consumers has nearly quadrupled in the four year period (2014-2018), from just 9% in 2014 to 33% in 2018. Further, roughly three-fourths of health consumers view wearables such as those that monitor glucose, heart rate, physical activity and sleep as beneficial to understanding their health condition (75%), engaging with their health (73%), and monitoring the health of a loved one (73%).

The smartwatch market is growing at a fast pace and isexpectedto reach a market value of $130.55billion by 2024 from $48.14billion in 2018, registering a CAGR of 18.23% during the forecast period (2019-2024).

Together, Apple, Samsung and Fitbit capture 72% of the market.

In 2018, Apple (AAPL)receivedDe Novo classification for the ECG app and the irregular heart rhythm notification from the Food and Drug Administration (FDA). The AppleWatchis capable of generating an ECG similar to a single-lead electrocardiogram; it can check the heart rate and alert a person about any irregularities. The Apple Watch comes with a vital fall detection feature and can even provide insight to women about their menstrual cycle. Not just smartwatches, Apple is working across the healthcare technology segment, something which has been echoed by Tim Cook in one of his interviews where hesaid, If you zoom out into the future, and you look back, and you ask the question, What was Apples greatest contribution to mankind? It will be about health.

Apples arch rival in the smartphone space, Samsung (SSNLF) is one of its closest competitors in the wrist wearables space as well. Samsung smartwatches help track heart rate, stress levels, sleep, water intake and much more. In June this year, the Galaxy Watch Activerevealedits anytime, anywhere blood pressure-checking capability using My BP Lab 2.0.

The global smartwatch shipments grew an impressive 42% annually to reach 14 million units in the third quarter of 2019. Apple Watch maintained first position with 48% global smartwatch market share, while Samsung held second place, and Fitbit (now acquired by Google) ranks at third,accordingto Strategy Analytics.

Fitbit (FIT) once enjoyed being the uncrowned king of the wearable device market, controlling a major market share untilthe Apple Watch came on the scene, and the dynamics started to change. Fitbitsold22.3 million connected health and fitness devices in 2016, while the same dropped to 13.9 million in 2018. The limited functionality of a fitness band when compared to a smartwatch has been a major reason for Fitbits shrinking market share. A CCS reporthighlights, Western consumers now find less value in the simple fitness bands, even with the added convenience of long battery life, preferring to move on to smartwatches, which offer all the functionality of fitness trackers and so much more.

Earlier this month, Google (GOOG,GOOGL) entered into a definitive agreement to acquire Fitbit for $2.1 billion. Over the years, Fitbit has sold more than 100 million devices and utilizes data to deliver unique personalized guidance and coaching to its users. While, Google introducedWear OSby Google back in 2014, and has been makingadvances in medical technologybut not particularly in wearables. Fitbit gives Google the opportunity to expandfurtherinto the wearables segment as well as introduce Made by Google wearable devices into the market.Back in 2018, Fitbit and Google collaborated to explore the development of consumer and enterprise health solutions. Last month, Fitbitannouncedan alliance with Bristol-Myers Squibb and Pfizer to help drive timely diagnosis of atrial fibrillation (AFib) with the aim of improving earlier detection in individuals at increased risk of stroke.

Fitbit and Google together can become a significant competitor to the existing market leaders in the wrist-wearables space. Wearables will assume a more significant role in the healthcare ecosystem and become a significant revenue generator for the technology providers. WHO Director-General Dr. Tedros Adhanom Ghebreyesus summarizesthe role of digital health technologies: Harnessing the power of digital technologies is essential for achieving universal health coverage. Ultimately, digital technologies are not an end in themselves; they are vital tools to promote health, keep the world safe, and serve the vulnerable.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more here:
Wearables and Healthcare: The 3 Companies Leading the Way - Nasdaq

Read More...

SLC22A1 And ATM Genes Polymorphisms Are Associated With The Risk Of Ty | TACG – Dove Medical Press

November 15th, 2019 8:43 pm

Rana M Altall,1 Safaa Y Qusti,1 Najlaa Filimban,2 Amani M Alhozali,3 Najat A Alotaibi,4 Ashraf Dallol,2 Adeel G Chaudhary,2 Sherin Bakhashab1,2

1Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia; 2KACST Technology Innovation Center in Personalized Medicine, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia; 3Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia; 4Department of Family and Community Medicine, Faculty of Medicine, King Abdulaziz University Hospital, Jeddah 21589, Kingdom of Saudi Arabia

Correspondence: Sherin BakhashabKing Abdulaziz University, P.O. Box 80218, Jeddah 21589, Kingdom of Saudi ArabiaTel +966 12 6400000Fax +966 12 6952076Email sbakhashab@kau.edu.sa

Introduction: Type 2 diabetes mellitus (T2DM) is a major global health problem that is progressively affected by genetic and environmental factors. The aim of this study is to determine the influence of solute carrier family 22 member 1 (SLC22A1) rs628031 and rs461473, and ataxia telangiectasia mutated (ATM) rs11212617 polymorphisms on the risk of T2DM in Saudi Arabia by considering many parameters associated with glycemic control of T2DM, such as body mass index (BMI), fasting blood glucose, glycated hemoglobin (HbA1c), and triglyceride.Methods: In a case-control study, genomic DNA from controls and diabetic groups was isolated and genotyped for each single-nucleotide polymorphism.Results: There were significant correlations between T2DM and both BMI and HbA1c. Significant associations between G/G and A/G genotypes of rs628031 and rs461473 variants of SLC22A1 and high levels of HbA1c were detected. Therefore, G was predicted to be the risk allele among the assessed SLC22A1 variants. A significant correlation was observed between A/A and A/C genotypes of the rs11212617 polymorphism of ATM and elevated HbA1c. Relative risk calculation confirmed A to be the risk allele in the T2DM population.Conclusion: Our study showed the risk of the assessed SLC22A1 and ATM variants on glycemic control parameters in diabetic patients.

Keywords: type 2 diabetes mellitus, single-nucleotide polymorphism, solute carrier family 22 member 1, ataxia telangiectasia mutated

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Link:
SLC22A1 And ATM Genes Polymorphisms Are Associated With The Risk Of Ty | TACG - Dove Medical Press

Read More...

Personalized Medicine Market Analysis by Top Companies, Driver, Existing Trends and Global Forecast by 2026 – WindStreetz

November 15th, 2019 8:43 pm

Personalized Medicine Market Overview:

The Personalized Medicine Market is expected to grow at a significant pace, reports Verified Market Research. Its latest research report, titled [Global Personalized Medicine Market Size and Forecast 2019-2026, Breakdown Data by Companies, Key Regions, Types and Application], offers a unique point of view about the global market. Analysts believe that the changing consumption patterns are expected to have a great influence on the overall market. For a brief overview of the global Personalized Medicine Market, the research report provides an executive summary. It explains the various factors that form an important element of the market. It includes the definition and the scope of the market with a detailed explanation of the market drivers, opportunities, restraints, and threats.

GlobalPersonalized Medicine Market: Segmentation

The chapters of segmentation allow the readers to understand the aspects of the market such as its products, available technologies, and applications of the same. These chapters are written in a manner to describe their development over the years and the course they are likely to take in the coming years. The research report also provides insightful information about the emerging trends that are likely to define progress of these segments in the coming years.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=WSN&utm_medium=AK

Key Players Mentioned in the Personalized Medicine Market Research Report:

Personalized Medicine Market: Regional Segmentation

For a deeper understanding, the research report includes geographical segmentation of the Personalized Medicine Market. It provides an evaluation of the volatility of the political scenarios and amends likely to be made to the regulatory structures. This assessment gives an accurate analysis of the regional-wise growth of the Personalized Medicine Market.

Personalized Medicine Market: Research Methodology

The research methodologies used by the analysts play an integral role in the way the publication has been collated. Analysts have used primary and secondary research methodologies to create a comprehensive analysis. For an accurate and precise analysis of the Personalized Medicine Market, analysts have bottom-up and top-down approaches.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=WSN&utm_medium=AK

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=WSN&utm_medium=AK

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. Our aim is to save your Time and Resources, providing you with the required Research Data, so you can only concentrate on Progress and Growth. Our Data includes research from various industries, along with all necessary statistics like Market Trends, or Forecasts from reliable sources.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email:sales@verifiedmarketresearch.com

Tag: Personalized Medicine Market Size, Personalized Medicine Market Growth, Personalized Medicine Market Analysis, Personalized Medicine Market Forecast, Personalized Medicine Market Outlook, Personalized Medicine Market Trends, Personalized Medicine Market Research, Personalized Medicine Market Report

Read the original:
Personalized Medicine Market Analysis by Top Companies, Driver, Existing Trends and Global Forecast by 2026 - WindStreetz

Read More...

Anatomic Pathology Market – Global Forecast to 2024: High Incidence of Cancer and Other Target Diseases Drives Growth – ResearchAndMarkets.com -…

November 15th, 2019 8:43 pm

DUBLIN--(BUSINESS WIRE)--The "Anatomic Pathology Market by Product & Service (Instruments (Tissue Processing Systems, Microtomes), Consumables (Antibodies), Histopathology), Application (Disease Diagnosis (Cancer (Gastrointestinal)), End User (Hospital, Lab) - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The anatomic pathology market is projected to reach a value of USD 44.4 billion by 2024 from USD 33.0 billion in 2019, at a CAGR of 6.1% during the forecast period.

The growth in this market is attributed to the high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine.

In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period. However, the availability of refurbished products, the lack of skilled professionals, and product recalls are expected to hamper the market growth to a certain extent in the coming years.

Disease diagnosis segment accounted for the larger share of the anatomic pathology market, by application, in 2018

Based on application, the anatomic pathology market is segmented into disease diagnosis and medical research. In 2018, the disease diagnosis segment accounted for the larger market share, due to the rapid growth in the geriatric population and the increasing incidence of cancer and other chronic diseases.

Hospital laboratories to register the highest growth in the anatomic pathology market during the forecast period

Based on end-user, the anatomic pathology market is segmented into clinical laboratories, hospital laboratories, and other end users. The hospital laboratories segment accounted for the largest market share in 2018 and is projected to register the highest CAGR during the forecast period. The growth of this segment can be attributed to the increasing number of patient visits to hospitals, a growing number of in-house diagnostic procedures performed in hospitals, growing awareness regarding early disease diagnosis, and the availability of reimbursements in developed markets for clinical tests performed in hospitals.

North America will continue to dominate the anatomic pathology market during the forecast period

Geographically, the anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest market share, followed by Europe. Factors such as the rising prevalence of chronic diseases, increasing healthcare expenditure, the high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the anatomic pathology market in North America.

Market Dynamics

Drivers

Opportunities

Challenges

Trends

List of Companies Profiled in the Report

For more information about this report visit https://www.researchandmarkets.com/r/i0353n

Read the original post:
Anatomic Pathology Market - Global Forecast to 2024: High Incidence of Cancer and Other Target Diseases Drives Growth - ResearchAndMarkets.com -...

Read More...

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After…

November 15th, 2019 8:43 pm

Introduction:Improved treatments are needed for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) pts. Options are particularly limited for pts with B-cell NHLs who are R/R to CAR-T therapies or for whom a delay in effective therapy precludes this approach. Mosunetuzumab (M; RG7828) is a full-length, fully humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both CD3 (on the surface of T cells) and CD20 (on the surface of B cells). In an ongoing Phase I/Ib study (GO29781; NCT02500407), promising efficacy and favorable tolerability were observed in R/R NHL pts (Budde et al. ASH 2018; Bartlett et al. ASCO 2019). We report complete remissions (CRs) with M in NHL pts who are R/R to CAR-T therapy, as well as activity with M re-treatment.

Methods:GO29781 is an open-label, multicenter, Phase I/Ib, dose escalation and expansion study of M in R/R B-cell NHL. Data is presented from Group B, in which M is administered with step-up dosing on Days 1, 8, and 15 of Cycle 1, and then as a fixed dose on Day 1 of each subsequent 21-day cycle (maximum 17 cycles). Outcome measures include best objective response rate (ORR) by revised International Working Group criteria, maximum tolerated dose (MTD), and tolerability.

Results:As of June 4, 2019, 218 pts in Group B had received any amount of M. Indolent NHL (iNHL) pts (n=72) were mainly follicular lymphoma (FL, n=69). Aggressive NHL (aNHL) pts (n=141) were mainly diffuse large B-cell lymphoma (DLBCL, n=87) or transformed FL (trFL, n=29). Median prior systemic therapies was 3 (range: 1-14). Twenty-three pts had prior CAR-T therapy (12 DLBCL, 6 trFL, 5 FL), and 16 were efficacy evaluable (7 DLBCL, 5 trFL, 4 FL). ORR and CR rates were 43.8% (7/16) and 25.0% (4/16, 2 DLBCL and 2 FL), respectively. Expansion of previously administered CAR-Ts after M administration was detected by quantitative PCR, in line with the mechanism of action of M.

Dose escalation is ongoing, supported by a positive exposure-response relationship for efficacy and broad therapeutic window with step-up dosing (Li et al. ASH 2019). Among efficacy-evaluable pts across all dose levels, ORR and CR rates were 64.1% (41/64) and 42.2% (27/64) in iNHL pts and 34.7% (41/119) and 18.6% (22/119) in aNHL pts, respectively.

CRs appeared durable, with 25/27 (92.6%) iNHL pts (median time from first CR: 5.8 months; range: 0.2-28.9) and 15/22 (68.2%) aNHL pts (median time from first CR: 8.8 months; range: 0.0-25.4) who achieved CR remaining in remission. Re-treatment with M was allowed in CR pts who relapsed. Four pts, including 1 in Group A who was initially treated with a fixed, non-step-up dosing schedule, received M re-treatment. One CR and 2 partial responses were observed. All three responses are ongoing, with the CR pt in second remission for 314 days.

The MTD of M has not been reached at doses up to 1/2/60mg (Cycle 1 Day 1, 8, and 15). Adverse events (AEs) leading to treatment withdrawal were uncommon (12/218, 5.5%). Cytokine release syndrome (CRS), graded by Lee criteria (Lee et al. Blood 2014;124:188-95), was observed in 28.4% of pts, and was mostly Grade (Gr) 1 (21.1%) or Gr 2 (6.0%); Gr 3 CRS occurred in 1.4% of pts. Most CRS events occurred in Cycle 1; 5 pts (2.7%) had CRS during or after Cycle 2. Three of 218 pts (1.4%) received tocilizumab for CRS management; all 3 events resolved without sequelae (for 1 pt, CRS resolved after the cutoff date). Neurological AEs (NAEs) were reported in 44% of pts (Gr 1, 28.0%; Gr 2, 12.8%; Gr 3, 3.2%). Common NAEs were headache (14.7%), insomnia (10.1%), and dizziness (9.2%). Potential immune effector cell-associated neurotoxicity syndrome (ICANS)-like NAEs of Gr 1 or Gr 2 confusional state occurred in 3 pts (1.4%) during cycles 1 and 2. The frequency of CRS and NAEs did not correlate with M exposure, likely due to step-up dosing, which effectively mitigates acute toxicities and allows administration of higher doses (Bartlett et al. ASCO 2019; Li et al. ASH 2019). Among the 4 pts who were re-treated with M, no CRS was observed and NAEs were reported in 1 pt (Gr 1 headache and insomnia). Among the 23 pts who were R/R to CAR-T therapy, CRS occurred in 5 pts (21.7%; Gr 1, 13.0%; Gr 2, 4.3%; Gr 3, 4.3%) and NAEs in 8 pts (34.8%; Gr 1, 17.4%; Gr 2, 13.0%; Gr 3, 4.3%), with no ICANS-like events.

Conclusions:M has favorable tolerability and durable efficacy in pts with heavily pre-treated R/R B-cell NHL, including CRs in pts with disease progression after CAR-T therapies. Preliminary data support the possibility for re-treatment with M.

Go here to see the original:
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After...

Read More...

The world’s first Gattaca baby tests are finally here – MIT Technology Review

November 14th, 2019 4:51 pm

Anxious couples are approaching fertility doctors in the US with requests for a hotly debated new genetic test being called 23andMe, but on embryos.

The baby-picking test is being offered by a New Jersey startup company, Genomic Prediction, whose plans we first reported on two years ago.

The company says it can use DNA measurements to predict which embryos from an IVF procedure are least likely to end up with any of 11 different common diseases. In the next few weeks it's set to release case studies on its first clients.

Handed report cards on a batch of frozen embryos, parents can use the test results to try to choose the healthiest ones. The grades include risk estimates for diabetes, heart attacks, and five types of cancer.

According to flyers distributed by the company, it will also warn clients about any embryo predicted to become a person who is among the shortest 2% of the population, or who is in the lowest 2% in intelligence.

The test is straight out of the science fiction film Gattaca, a movie thats one of the inspirations of the startups CEO, Laurent Tellier. The companys other cofounders are testing expert Nathan Treff and Stephen Hsu, a Michigan State University administrator and media pundit.

So far, fertility centers have not leaped at the chance to offer the test, which is new and unproven. Instead, prospective parents are learning about the designer baby reports through word of mouth or news articles and taking the companys flyer to their doctors.

One such couple recently turned up at New York Universitys fertility center in Manhattan, says David Keefe, who is chairman of obstetrics and gynecology there. Right off the bat it raises all kind of questions about eugenics, he says.

Keefe, who has seven children, worries that couples who think they can choose kids from a menu could be disappointed. Its fraught with parenting issues, he says. So many couples just need to feel they have done enough.

Picking your baby

The companys project remains at a preliminary stage. While some embryos have been tested by the company, Tellier, the CEO, says he is unsure if any have yet been used to initiate a pregnancy.

The test is carried out on a few cells plucked from a days-old IVF embryo. Then Genomic Prediction measures its DNA at several hundred thousand genetic positions, from which it says it can create a statistical estimate, called a polygenic score, of the chance of disease later in life.

Genomic prediction

In October, the company pitched the test, which it calls LifeView, from a trade-show booth at the annual meeting of fertility doctors in Philadelphia. A promotional banner read: She has your partners ears and smile. Just not their risk of diabetes.

Criticism of the company from some genetics researchers has been intense.

It is irresponsible to suggest that the science is at the point where we could reliably predict which embryo to select to minimize the risk of disease. The science simply isnt there yet, says Graham Coop, a geneticist at the University of California, Davis, and a frequent critic of the company on Twitter.

The company has raised several million dollars in venture capital from investors including People Fund, Arab Angel, Passport Capital, and Sam Altman, the chairman of Y Combinator and CEO of OpenAI.

At an investor event last April, Genomic Prediction compared itself to 23andMe for IVF clinics and boasted it was preparing for a massive marketing push.

Our reporting suggests the company has struggled both to validate its predictions and to interest fertility centers in them. Its customers so far seem to be a scattering of individuals from around the world with specific family health worries. The company declined to name them, citing confidentiality.

The company is expected to soon present its first case reports, describing clients and their embryo test results. One case involves a married gay couple who have begun IVF using donor eggs and plan to employ a surrogate mother. That couple wants a child with a low risk for breast cancer.

How will it be used?

Genomic Prediction thinks it can piggyback on the most common type of preimplantation embryo test, which screens days-old embryos for major chromosome abnormalities, called aneuploidies. Such testing has become widespread in fertility centers for older mothers and is already employed in nearly a third of IVF attempts in the US. The new predictions could be added to it.

Fertility centers can also order tests for specific genetic diseases, such as cystic fibrosis, where a gene measurement will give a definite diagnosis of what embryo inherited the problem The new polygenic tests are more like forecasts, estimating risk for common diseases on the basis of variations in hundreds or thousands of genes, each with a small effect.

In a legal disclaimer, the company says it cant guarantee anything about the resulting child and that the assessment is NOT a diagnostic test.

Santiago Munne, an embryo testing expert and entrepreneur, thinks patients already undergoing aneuploidy testing would likely want the add-on test, but that doctors could object if it introduces uncertainty: For monogenic disease, if the embryo is abnormal, we will tell you, and it is. With a risk score, it may be affected. And some patients will only have embryos with higher risks. Then what?

As well, he says it wont be possible with a test to optimize a child for many features at once: My personal opinion is once you start looking, some embryos will be brighter, some will be taller, some will have longevity, and none will have those qualities all together. And in an IVF cycle, you produce maybe six embryos on average. You wont be able to get all the traits that you want.

Despite such inherent limits, theres a bigger plan afoot. Treff, the startup's chief scientist, believes even fertile couples might begin to undergo IVF just so they can select the best child. I do believe this is going to be the future we can start to ... reduce the incidence of disease in humans through IVF, Treff told an audience at a conference in China last month.

How many people will be willing to go through the trouble of IVF if they dont need it to have a baby? IVF involves weeks of hormone shots and two medical procedures (one to collect eggs, another to implant the embryos) and typically costs around $15,000. Add to that the companys fee to test embryos, which is $1,000, plus $400 for each embryo scored.

If someone is fertile, unless there is a family history of disease, I dont think that it is going to be popular, says Munne.

Can you get a smarter baby?

Genomic Prediction has so far won the most attention for the possibility of using genetic scores to pick the most intelligent children from a petri dish. It has tried to distance itself from the controversial concept, but thats been difficult because Hsu, a cofounder, is frequently in the media discussing the idea.

Hsu told The Guardian this year that accurate IQ predictors will be possible if not in the next five years, the next 10 years certainly. He says other countries, or the ultra-wealthy, might be the first to try to boost IQ in their kids this way.

During his talk in China, Treff called improving intelligence via embryo selection an application that many people think is unethical." In private, Treff tells other scientists he thinks it's doable, but wants to promote the technology for medical purposes only.

Ms Tech

For now, the company is limiting itself to alerting parents to embryos it predicts will be the least intelligent, with the highest chance of an IQ which qualifies as intellectual disability according to psychiatric manuals.

Some experts see a transparent maneuver to avoid controversy. They say theyre going to test for the medical condition of intellectual disability, not for the smartest embryos, because they know people are going to object to that, says Laura Hercher, who trains genetic counselors at Sarah Lawrence College. They are trying to slide, slide into traits without admitting as much.

A May report from the Hebrew University of Jerusalem found that trying to pick the tallest or smartest embryos might not work particularly well. Researchers there estimated that using polygenic scores to locate the tallest or smartest child from a batch of sibling embryos would result in an average gain of 2.5 centimeters in height, and less than three IQ points.

They modeled what everyone is scared of happening, Treff said of that study. Its not what we are doing.

The predictions, however, could be more effective at helping people avoid children with specific diseases. Treff, during his speech in China, said that a couple choosing between two embryos would see, on average, a 45% reduction in risk for type 1 diabetes. That is a serious disease from which Treff suffers and which runs in families, although it has complex causes. The more embryos there are to choose from, he says, the more the risk will go down.

Demand for the test

Patients and doctors are mostly on their own when it comes to deciding if the tests really work. While federal and state agencies do oversee laboratory accuracy, the oversight is limited to whether analytes like DNA are correctly measured, not what they mean. So Genomic Prediction doesnt need to prove that the test is useful before selling it. In fact, it could take decades to ascertain if tested kids fare better than others.

Sign up for The Download your daily dose of what's up in emerging technology

And its not only whether the test works or not. Uptake will depend on demand from patients and the degree of pushback from doctors and genetic counselors. In the US, tests for genderthat is, picking a boy or a girl embryoare accepted and relatively routine. But thats never become the case for choosing eye color, which is also possible. In terms of eye color, the pressure not to do it, to not offer it, was met with a weak market demand. So it doesnt exist, says Hercher.

Genomic Prediction provided a map of 12 fertility clinics it says will order its test, including five in the US and others in Nigeria, Peru, Thailand, and Taiwan.

MIT Technology Review was able to independently locate two IVF clinics where customers have recently requested the embryo predictions. Michael Alper, founder of Boston IVF, one of the worlds largest fertility clinics, says his center was approached by a couple a few weeks ago but he decided the request needs to be weighed by the centers ethics committee before he would agree to order it.

This is the first case we have had, says Alper. To me its a 23andMe type of prediction: theres a propensity, but how strong? That is the problem. We dont have any problem testing for cystic fibrosisthat is a lethal disease, it strikes young. But we are not there yet with these other tests. Its soft; its not that predictive.

At NYU, Keefe says the test raises profound questions. His center is in Midtown Manhattan, just blocks from a hub of finance and legal offices. He says his clientele are typically well-off professionals, people who have programmed everything in life and feel they are in control. They sometimes even ask out loud if a mere doctor is smart enough to help them.

The case he is working on involves a family that has two children with autism. They now want a child without the condition, and they hope the intelligence feature of the test will help them. Treff says he counseled the family that the Genomic Prediction test wasnt likely to helpautism can have specific genetic causes that the intelligence prediction isnt designed to capture.

Yet the family remains interested. They want to do whatever they can to have a healthy kid. Keefe says hes so far supporting their choice, but he is concerned by all that it implies. There is potential psychological harm to the kid, he says. God forbid the kids ends up with autism after spending this money.

View post:
The world's first Gattaca baby tests are finally here - MIT Technology Review

Read More...

A short guide to regulation for disruptive technologies – Lexology

November 14th, 2019 4:51 pm

Introduction

Regulation, by necessity, introduces rigidity to otherwise flexible processes. Done proportionately, this can be an efficient societal device for preventing harm. At the same time, inherent regulatory rigidity creates particular challenges when the nature of the regulatory target changes quickly or unexpectedly.

Disruptive technologies in life sciences - a very dynamic field of activity are a good example of this. Disruptive technologies challenge the way a sector operates, and it is self-evident that (in most cases) this will also have an impact on the relevant normative framework. This effect is most visible in areas which have a direct impact on human life and wellbeing, as these areas are tightly (and often, rather specifically) regulated, and a failure to control a technology appropriately may lead to undesirable outcomes.

The dual purposes of preventing harm through proportionate regulation and maintaining trust in innovation mean that it is all the more important to ensure that regulation is adequately responsive and flexible to react to a disruptive technology. This can be a difficult line to tread, particularly in fields where research and development is also morally or ethically contentious.

We will illustrate the context and challenge of regulating disruptive technologies by discussing two specific case studies: artificial intelligence, and cell and gene therapy. In both cases, we suggest that the current regulatory framework in the UK strikes an appropriate balance between precaution and freedom of research, allowing for innovation subject to strict controls and licensing frameworks. There are, however, numerous challenges which need to be considered and addressed as these technologies advance. Regulators, policy makers and innovators working in this sector must continue to work together to ensure that responsible science is allowed to flourish.

Artificial intelligence

The science of making machines do things that would require intelligence if done by people (Definition of artificial intelligence from the Proposal for the Dartmouth Summer Research Project on Artificial Intelligence, 1955.)

Artificial intelligence (AI) technologies hold the potential to significantly improve health and care, providing faster and more accurate diagnosis, speedier treatments, and facilitating medical breakthroughs through drug discovery.

This is particularly the case in contexts where the pattern-recognition strengths of AI can be deployed to their fullest potential. Tasks such as the correct identification of tumour cells, recognition of areas of concern in medical imaging, and the processing of large amounts of genomic data can be carried out with much greater speed and accuracy by algorithms that learn from previous datasets, and develop their own datasets from which to learn from in the future. The ability to check a patients image or test result against all other available and comparable datasets is, at first glance, far superior to a clinicians ability to make an assessment on the basis of his or her experience.

At the same time, this does give rise to risk. For example, there is an inherent (and proven) risk that an algorithm which learns on the basis of historic human-generated data also takes on the biases that human decision-making has inevitably introduced. So how does regulation play a part in addressing this risk?

The first point to make is that no one body is solely responsible for regulating the adoption of AI technologies in the UK healthcare sector. A number of different regulatory bodies have a remit to oversee aspects of AI, including the Medicines and Healthcare products Regulatory Agency (MHRA) and the Information Commissioners Office (ICO). In addition, there are nonregulatory bodies which also play an important role, including the National Institute for Health and Care Excellence (NICE) and NHSX. However, no one institution has overall responsibility for policing, for example, the prevention of bias in AI algorithms. The most effective way of addressing this risk at present is to avoid exclusively automated decision-making so that the use of AI technologies in the clinical setting will focus instead on assisted decision-making and triage. The application of this approach will come down to individual healthcare payors and providers: in the absence of any direct regulation, it is left to them to decide how best to mitigate risk, and whether and if so how to apply nonbinding codes of conduct, such as the Department of Health and Social Cares code of conduct for data-driven technologies which seek to address the risk.

Reliance on nonbinding codes of conduct as a substitute for regulation may not be ideal and can result in a lack of certainty. Equally, overlapping codes, rules and regulations also pose a risk, for example, as to how NICEs evidence standards framework for digital health technologies interacts with MHRA regulations concerning software as a medical device in relation to clinical evidence. The risk is lack of clarity; the mitigation is raising awareness.

Another challenge arises where regulation designed for a specific purpose is used for a new purpose, for example the application of MHRA regulations designed for traditional medical devices to software incorporating algorithms. A recent state of the nation survey on the use of AI in health and care revealed that half of all software developers were not intending to seek CE mark classification, with the most commonly cited reason being that they did not believe the medical device classification was applicable. It is essential that the sector raises awareness of these requirements, albeit that they are complex and sometimes impenetrable.

One significant area of concern is how existing laws relating to negligence, liability and insurance apply to the clinical use of AI whether in assisting decision-making about a patients treatment, or in the operation of medical devices. Currently, claims are almost always brought against the treating clinician or healthcare provider, but for a clinician using big data analysis as well as his or her own experience, where does the division of responsibility lie? If a patient is injured as a result of a malfunction in an AI-driven device, does liability lie with the manufacturer of the device, the programmer who wrote the code which operates the device, the clinical team, the hospital or all of the above? It remains to be seen whether this will give rise to novel constellations of liability, such as an increase in manufacturers liability or a change in statutory and wider insurance requirements.

One of the major areas of opportunity for AI-based technologies is biomedical research where the strengths of speed and range have huge potential. The extrapolation of the potential of certain compounds against huge databases of similar compounds is commercially powerful. The ability to quickly check clinical trial design against public registries of published results to avoid unnecessary duplication of human-based experimentation is ethically desirable. But as innovators seek to improve drug discovery using AI, it will be important to continue to keep under review laws relating to intellectual property and how they apply to AI-based technologies.

Cell and gene therapy

The area of cell and gene therapy is of particular significance, and great potential, in regenerative medicine. It has seen a decade-long genesis since its inception, and it does not immediately strike one as a field that meets the definition of a disruptive technology. At the same time, however, it provides a good illustration of how a technology may mature for a long time, or be repurposed in an unexpected way, before it becomes disruptive.

The field has come a long way since the first systematic trials in 1989, and by now, there are 17 FDA-approved cell and gene therapy products. Over and beyond technical questions of the safety of the vectors used for the manipulation of cells, there are few remaining ethical and legal issues in relation to somatic cell gene therapy for particularly debilitating conditions (i.e. where the manipulation does not lead to heritable genetic characteristics).

From a regulatory and ethical perspective, however, cell and gene therapy becomes more complex where germline gene therapy is used. The modification of the human germline is subject to significant debate and, in some jurisdictions, strongly prohibitive regulation. The advent of disruptive technologies such as CRISPR/Cas9 prime editing techniques, with their associated precision and purported safety, have already reignited the debate around the prohibition of germline manipulation, with some commentators calling for a relaxation of the regulation while others demand either a global ban or at least a moratorium.

Although the United Kingdom has a reputation of being a liberal jurisdiction for research, it is in fact very tightly regulated and only potentially permissive. UK law reects a compromise: we permit research (including research involving germline gene editing), but we subject such research to strict scrutiny, licensing and oversight, and we criminalise unlicensed research. That being said, the legislation is drafted in such a way as to facilitate a broad variety of research, including (again, potentially) the introduction of novel techniques, and few procedures are prohibited. Overall, this framework helps allay public and political concern about what is often controversial research and provides a degree of protection for researchers operating under a licence, facilitating innovation. Such a robust framework is particularly valuable when it comes to considering how best to address the clinical application of germline genome modication. In circumstances where UK law is comprehensive and clear in its application to gene editing, there is no merit or purpose in a moratorium or further restriction on the use of this technology as some have demanded.

Concluding remarks

The UK has a mature and robust regulatory framework governing research and development in life sciences. We have a successful history in regulating numerous disruptive and controversial new technologies, such as stem cell research, the creation of human-animal hybrids, the clinical use of preimplantation genetics, and mitochondrial donation all testaments to the strength of this framework and its capacity to adapt to accommodate new technologies. This success, however, has been built upon a vital foundation of open and accessible dialogue between innovators, parliamentarians, policy makers and the public, and it is to be hoped that a similar transparency will be maintained in the future. Such dialogue will also ensure that if there are gaps or restrictions in regulation that need to be addressed to avoid stifling innovation, these can be pre-empted.

See the original post:
A short guide to regulation for disruptive technologies - Lexology

Read More...

Mirza Dinnayi’s Aid to Terror Victims Recognized with Aurora Prize – The Armenian Mirror-Spectator

November 14th, 2019 4:51 pm

In Germany, he became engaged in many Yazidi cultural activities, advocated for the rights of non-Muslim minorities in Iraq, and worked for peace and coexistence. After the fall of the Saddam regime in 2003, when Kurdish leader Jalal Talabani became interim president of Iraq, he invited Dinnayi to become his advisor for non-Muslim minorities. Dinnayi said he stayed there from 2004 to 2005 but it was hard for him to reintegrate into Iraqi society after becoming used to a German lifestyle. More importantly, a civil war had engulfed Baghdad by 2006 and 2007 and death was always around the corner. His family would call every few days to ask what he was doing there.

After this, he became an advisor for some ten years to the Kurdish Regional Government (KRG) in Erbil concerning disputed regions, which include Yazidi, Christian and Turkmen populated areas, claimed by both the KRG and the central government.

Air Bridge Iraq

On August 14, 2007, Dinnayi was in Germany when the extremist Sunni Muslim terror organization al-Qaeda attacked two Yazidi villages near Mosul in Iraq, killing more than 300 people and injuring more than 850 with truck bombs inside the villages and markets. About 60 children were among the latter.

By this point, Dinnayi had studied both medicine and law, and though not a practicing doctor, knew what the needs were. He did fundraising in Germany for the victims and then went as a volunteer to distribute the money and aid. When he saw many children in the hospital who would die soon without help, he posted an appeal in a German newspaper, Neue Osnabrcker Zeitung, asking for hospitals to host some of these child victims. Two hospitals agreed.

The real challenges then began. Dinnayi said that as the children were from villages, they did not have any passports or identification papers, and the age of one child, who had no family left, was not clear. Dinnayi asked the Iraqi government to issue some kind of passport for them. He also spoke with the German ambassador in Iraq, and explained the emergency. As Dinnayi had dealt with him before when he was an advisor to the government, he trusted Dinnayis judgment and agreed to issue visas within days of receiving the passports. This was a big risk for the embassy because, explained Dinnayi, there was no German NGO in Iraq at the time because of the civil war, and no one believed that Dinnayi would return the children to Iraq after treatment.

Within three days, the passports arrived. The problem, Dinnayi said, was that all Baghdad was a ball of fire. A friend at the German embassy requested that Dinnayi stay in the hotel until going to the airport. As a German citizen, if Dinnayi went outside, he might be kidnapped and cause the government problems.

Yet the hotel happened to have been attacked by al-Qaeda three or four weeks prior and activists and politicians staying there had been killed. Half of the hotel had been destroyed and food was not available.

Dinnayi took the passports and visas of the six children in the first group and went to Erbil, from which he planned to take a charter flight to Germany. The German embassy did not allow family members to go.Some of the children receiving treatment in 2007 (photo courtesy Mirza Dinnayi)

He said, So you can imagine, I had a 6-year-old child who cannot speak, barely walking. I had a girl with broken legs in a wheelchair. I had two other boys, also in wheelchairs. So I was alone with those six children.

An ambulance took them to the airport, but after a wait of two hours, they were told that Turkey would not allow the charter flight to pass through its airspace.

Dinnayi said, The children were very upset. The families told me, you brought the children 150 kilometers from Dohuk to the airport. Now they cannot fly what are you doing? Everybody was blaming me. He took the children to a hotel and the next day got them tickets for a flight to Istanbul. There they booked an airport hotel to stay overnight, and a flight to Dsseldorf, Germany, the next day.

The next morning at the Istanbul airport, the person responsible for check-in refused to let the children on because the flight had no medical equipment. Dinnayi had no choice but to ask for the manager and play hardball. He recalled that he said, These six children are victims of the al-Qaeda terror organization. You have a choice. I can call BBC and CNN in Istanbul and tell them that al-Qaeda killed the innocent minorities of Iraq but the Turks are not allowing us go, or you will bring me a piece of paper and I will sign that all that happens to the children is my responsibility. I will not charge anything. I will not ask for any compensation if anything happens. I am responsible alone in person.

This was accepted, and after the children were treated for about two months in Germany, Dinnayi brought them back to Iraq successfully.

At this point, he thought that since there is no German humanitarian organization in Iraq he and his German friends might as well make one. He said, We called it Luftbrcke Irak because of the Luftbrcke Berlin after Second World War, which also provided humanitarian aid via the air. It was formalized as an organization in November 2008 (see https://luftbruecke-irak.de/?lang=en) and it helps terror victims of all creeds and backgrounds.

From 2007 to the present, all funding has been from private donors and friends. The host families in Germany, along with volunteer workers, do not receive any pay. Approximately 150 children from all over Iraq and from all religious communities (Muslim, Christian, Yazidi etc.) have received treatment in all. This does not include work to aid survivors of the 2014 genocide of Yazidis attempted by ISIS.. Mirza Dinnayi with Lamya Haji Bashar at the International Criminal Court, October 14, 2016. Haji Bashar was forced by ISIS into sexual slavery. She escaped in 2016 but was injured by a land mine. Dinnayis Air Bridge Iraq helped her obtain medical treatment and she became an activist for the Yazidis. In recognition of her human rights achievements, she was given the Sakharov Prize of the European Union. (photo courtesy Mirza Dinnayi)

Assistance to Yazidi Victims of ISIS

Dinnayi was in Erbil for his job as advisor to the KRG as Mosul fell under the control of ISIS on June 10, 2014. He was planning to return to Germany for a summer vacation with his family but he called his wife to cancel, declaring that he feared a huge catastrophe would soon occur. Indeed, two months later, the Yazidis in Sinjar were attacked and the entire community displaced. When 325,000 people went to the mountain it was a huge problem due to the lack of water and food.

Dinnayi was engaged in lobbying, meeting every day with diplomats to try to convince the international community to act. The whole mountain area was occupied by ISIS and the safe zone was 150 kilometers away. For this reason, the Iraqi government decided to initiate a humanitarian mission via helicopter from the Kurdish area to bring food and water there and extract vulnerable people to the safe area.

Dinnayi volunteered to fly with the helicopters, he said, because he knew all the areas where the refugees had collected and was in contact with them. Nearly every day he was with the flights, which were being shot at by ISIS. The helicopters were very old Russian Mi-17 models which were supposed to hold 20-25 people and yet each time they picked up 40-50 people.

One day, Dinnayi said, our helicopter crashed because of overload and I broke my leg. Unfortunately. I lost my friend who was the pilot and some of the refugees died. But we were very lucky, because the crash was over the mount.

Dinnayi was in a wheelchair for three months as his leg and broken ribs healed. He came to Germany and then to Geneva only one week after his return to speak at the UN Human Rights Council on the Yazidis, which led to an investigation about the Yazidi Genocide.Mirza Dinnayi receives a medal as Aurora Humanitarian from the 2011 Liberian Nobel Peace Laureate and Aurora Selection Committee member Leymah Gbowee (Aram Arkun photo)

Helping Yazidi Girls and Women

Only 1 weeks later he returned to Iraq and met the first group of girls who had been raped by ISIS. He said, I was ashamed to hear these stories of atrocities, as a man, to hear what happened with those innocent girls of 16, 17 years old. I decided, I said, well, the catastrophe of the Yazidis and the plight of the Yazidi people is so huge that maybe I cannot help them in all the issues, but maybe I can do something for those women and children. And this was the reason that I concentrated my work to help the survivors of ISIS, and the women and children especially, who were sexually abused.

He helped pressure the Yazidi Spiritual Council to accept these women, because in the beginning the Yazidi community itself would not accept them. Fortunately, the Yazidi religious leader or Baba Sheikh accepted these children and women. Yet, Dinnayi realized, there is no medical or psychological aid for these traumatized beings in Iraq. There is only one psychotherapist per every 250,000 people in Iraq, and generally that person has no experience in trauma.

One of the German states, Baden-Wrttemberg, decided to accept up to one thousand of the women and children victimized by ISIS. The Germans asked Dinnayi to lead this project. Dinnayi did this as a volunteer, and his NGO became a partner of the German project. A German team from the government ministry led and decided for the project, but Dinnayi led the receiving commission in Iraq.

Within almost 9 months, 1,100 women and children were resettled through this project. Dinnayi said it was a very, very hard job. He worked 18 hours a day and had to interview all the women and children. He said, I myself was traumatized, because you hear every day 20 stories of rape, and you ask yourself, every time, why did people do that to those innocent women. I saw 9-year-old or 11-year-old girls who were pregnant because they were raped 20 times or 30 times. In the summer of 2015, I was actually at the end. I couldnt sleep. I was crying every day. I came back to my family, to my wife and children living in Germany. And I told them, okay, lets go and take three days vacation.Mirza Dinnayi surrounded by the founders of the Aurora Prize at Yerevans Freedom Square after he was announced as the 2019 Aurora Prize Laureate (Aram Arkun photo)

During those three days, he debated with himself whether he should withdraw from the project and seek psychological treatment himself. At the end, he decided that if he withdrew, the project would collapse because no one could live under such stress. On the other hand, he said that if he continued, it is only helping me, because I see these atrocities and besides that I see that I can help those victims so maybe this will help to heal my trauma. And I was lucky, that I had overcome this trauma. Until now, I have these traumatic ideas.

The project also had various bureaucratic hurdles to be overcome. The Germans required detailed files on each woman, each between 11 and 32 pages, which Dinnayi had to translate. Then most of the husbands of the women had been killed or were missing, so they were not allowed to get passports for the children nor to fly without their husbands.

Dinnayi went to Iraqi civil courts and asked them to issue a temporary guardian certificate for the children, with which passports could be obtained. When children did not have family, Dinnayi ended up being the guardian.

He had no time for anything but work. Dinnayi related, The problem was that I even forgot day and night during the project, because I was sleeping one night in Duhok (my office was in Duhok), and then I went with the beneficiaries to Erbil, almost two hundred kilometers, sleeping one night there; flying in a special charter with 60 or 70 people to Stuttgart, Germany, sleeping one night in Stuttgart, then moving by train to my family, sleeping one night there, then coming back to Erbil because I had to prepare the next mission. So I was during four days in four different placesSo every time, it was like a joke, before I opened my eyes. Am I at home, I shouldnt do a mistake at least in front of my wifewhere is the bathroom?

Dinnayi said, I am so happy when I compare the situation of those women and children who we got to Germany and the children and women who are still in the camps. There is a big difference. The children are very well integrated. They still have this pain. There is an injury inside them that we are not able heal, unfortunately, because you cannot return back to them their pasts, and you cannot bring their relatives back to them, but their lives are secure, they are no longer living in tents.

The girls and women got visas for two years and there were 22 municipalities in the state of Baden-Wrttemberg state which placed those women in special houses. There they had 24-hour translators, a social worker would take care of them, and each family had its privacy. After 2 years they were moved to regular housing units, the children went to school and the women went to treatment. This was the first time in the history of Germany that a state undertook such a project, Dinnayi said, which is why the project is so unique.

After this, the Canadians started another project for resettlement and took a couple of hundred of the women and the Australians did the same. No Americans helped.

Yazidis and ArmeniansThe new Yazidi temple Quba Mere Diwane at Aknalich, Armenia (Aram Arkun photo)

Dinnayi speaks often about the special relationship between Armenians and Yazidis.

The Armenian parliament and now the Aurora Prize have provided special recognition to the Yazidi Genocide. He said, This is the first time that the Yazidi were accepted and we are so lucky that Armenia, especially the grandchildren of a previous genocide 100 years ago, recognized this genocide. Furthermore, he said, Through the establishment of this forum and this prize Armenia became one of the greatest nations, because they are in solidarity with the victims of genocide.

In general, he said, The Yazidi community in Armenia is a well-integrated community in Armenia. He noted the recent building of a new Yazidi temple in Armenia and contrasted that to the situation in Iraq. If a temple would be destroyed in Iraq, there would be no possibility of rebuilding it, as Yazidis are treated as infidels.

He said, I think we share a cultural heritage together, but unfortunately we also share a history of pain. Aside from culture, Dinnayi has found that there are even close genetic connections between Yazidis and Armenians. He said, I did a DNA investigation with the Family Tree DNA laboratory in the US on some 30 Yazidis from Iraq and the nearest population to the Yazidis was the Armenians. In my family tree, I have more than 100 matches of which many, many are Armenian; 75 percent of my matches were from Armenia and Asia Minor.

The Future

Prior to the Aurora Prize, Dinnayi had another small humanitarian project in Iraq, but at present he said he was mainly working for the recognition of the Yazidi Genocide in Europe, especially with the European Parliament. The latter has passed various resolutions, but what he wants, he said, is to have a special tribunal, either a hybrid tribunal for the crimes of ISIS concerning the Yazidi Genocide, or an internationalized Iraqi tribunal to bring those ISIS fighters to justice and try them according to the international conventions about genocide. While many ISIS fighters are in prisons, they are being tried according to the Iraqi anti-terror law or the Iraqi penal code and not in connection with genocide or international crimes in general. Dinnayi said that the Iraqi penal code is a jokeit is very easy for rapists, for example, to have impunity and overturn any punishment due to a provision allowing this if a certificate of marriage is presented afterwards.

Dinnayi noted that many countries, among them Armenia, symbolically recognized through their parliaments the Yazidi Genocide, which he said is very good and important. He added, We know that this challenge will take a long time. We know about the Armenian Genocide, that it took 100 years until some countries said yes, while the perpetrators until now say no, this was not a genocideSo you see how difficult a situation it is.

He is also working to persuade other countries to accept more women and more victims, though there are no new projects in this vein so far. In the past five years, Dinnayi said, little has changed. Around 80 percent of the Yazidis from Sinjar remain refugees or internally displaced persons in the camps in Kurdistan or outside of Iraq. The people refuse to return to their villages, he said, while those who remain seek an opportunity to leave.

Among the problems is the corruption of the current Iraqi government. It took no steps towards transitional justice and reconciliation. The future, not only for the Yazidis but also the Christians and Mandaeans, is bleak, he said, if there is no special zone or a kind of autonomy established in Sinjar, or the Nineveh plain for Christians. Furthermore, although ISIS is not in this area at present, militias and the Iranian-Turkish conflict create instability.

Meanwhile, Dinnayi is afraid that the Turkish invasion of Syria may lead to a big wave of refugees coming to Sinjar. He exclaimed, I hope that the international pressure on President Trump, on the Europeans, will put enough pressure on Mr. Erdogan to stop this invasion, because it is against humanity, it is against international law. All the Yazidis meanwhile have been deported or displaced from places like Afrin, Syria, over the last five years. There used to be around 35,000 Yazidis there. Some were forcibly converted to Islam.

Going forward, Dinnayi has no intention to slow down.

Dinnayi will continue his work, despite paying a heavy personal price, including health issues. He declared, If you start humanitarian work, you will be part of this humanitarian family and you cannot stop any more. Because you are in direct touch with the victims, with the people in need, with the vulnerable children women, men, and if you stop for one minute, you will feel guilty and you cannot stop more. This was the reason [I continue my work]. I was not expecting to get a prize from any people.

See the rest here:
Mirza Dinnayi's Aid to Terror Victims Recognized with Aurora Prize - The Armenian Mirror-Spectator

Read More...

Global Carrier Screening Market to reach $2.93 billion by 2029 according to a new research report – WhaTech – WhaTech

November 14th, 2019 4:51 pm

The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029.

According to a new market intelligence report by BIS Research, titled Global Carrier Screening Market- Analysis and Forecast, 2019-2029, the global carrier screening market was valued at $846.9 million in 2018, and is estimated to grow over $2.93 billion by 2029. The global carrier screening market is expected to grow at a compound annual growth rate (CAGR) of 11.59% during the forecast period from 2019 to 2029.

The development of the market is aided by the impressive growth in the field of non-invasive prenatal testing (NIPT), genetic testing, and precision medicine.

Browse 16 Market Data Tables and 142 Figures spread through 201 Pages and in-depth TOC on "Global Carrier Screening Market"

Genetic diseases are the leading cause of the infant death, accounting for approximately 20% of annual infant mortality in the U.S. Advancements in the technological platforms in the genomic medicine have made possible low cost, pan-ethnic expanded carrier screening, enabling obstetric care providers to offer screening for over 100 recessive genetic disorders.

However, the rapid integration of use of genomic medicine into routine obstetric practices has eventually raised concerns about the implementation of carrier testing.

Technological and other advancements over the past decade have led to the discovery of thousands of genes that are associated with autosomal and X-linked recessive Mendelian disorders. Recent improvements in assessing the individual variants in the human genome, generally offer the possibility of testing populations for all known severe recessive genetic disorders.

For decades, general population carrier screening was based on the clinical validity and the utility to direct services based on ethnicity, social factors or race that may lead to particular conditions being more common in a particular group. With advancement in genetic knowledge and technologies, carrier screening for disorders such as cystic fibrosis has now become a part of primary care.

BIS Research Report: bisresearch.com/industrarket.html

With genetic screening, arises several important legal issues such as insurance and employment discrimination, confidentiality, and informed consent for both testing and treatment. Approximately, seven states have laws that penalize providers for violating a patients privacy regarding the genetic information of patients and 27 states require consent for disclosure of genetic information to the third parties.

According to Wahid Khan, Principal Analyst at BIS Research North America is the leading contributor to the global carrier screening market and is noticed to be contributing more than 51.82% of the global market value. However, Asia-Pacific is expected to grow at an impressive CAGR of 15.97% during the forecast period from 2019 to 2029.

Currently, the Asia-Pacific market is estimated to contribute approximately 15.11% of total global market value.

Research Highlights:

Report: bisresearch.com/requeste=download

This market intelligence report provides a multidimensional view of the global carrier screening market in terms of market size and growth potential. This research report aims at answering various aspects of the global carrier screening market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches, regulatory clearance, and certifications, partnerships, collaborations, business expansions as well as mergers and acquisitions. The research report provides a comprehensive analysis of the product sales and manufacturers and trend analysis by segment and demand analysis by geographical region.

This report is a meticulous compilation of research on more than 30 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The report also profiles 15 key companies, namely, Illumina, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Natera, Inc., Invitae Corporation, Eurofins Scientific, GenMark Diagnostics, 23and Me, Inc., Sema4, BGI, Centogene AG, Pathway Genomics, and Gene By Gene.

Key Questions Answered in the Report:

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more here:
Global Carrier Screening Market to reach $2.93 billion by 2029 according to a new research report - WhaTech - WhaTech

Read More...

Treatment-free Remission at Heart of New CML Study – AJMC.com Managed Markets Network

November 14th, 2019 4:48 pm

Maggie L. Shaw

Researchers aim to eliminate leukemia stem cells safely.

Its like removing the tree, but leaving the roots that can sprout new shoots, they said in a statement.

Because stem cells are responsible for cell self-renewal and differentiation, Lacorazza and his team set out to better understand the LSC self-renewal process, hoping to pinpoint possible new options to target that activity, prevent relapses, and lead to treatment-free remission. Their results appeared recently in Blood, the official publication of the American Society of Hematology.

Knowing that Krppel-like factor 4 (KLF4) plays an essential part in carcinogenesisalthough it has also been shown to have antitumor activitythe study investigators removed KLF4 to see if it was necessary also for LSCs to survive. The result? Loss of LSC/progenitor cells and increased levels of tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) protein.

According to the authors, A major change in the absence of KLF4 was an increase in the production of kinase DYRK2, an enzyme involved in protein stability, cell cycle control, and apoptosis.

Stabilizing levels of this protein, then, could be a possible solution. To do this, they inhibited ubiquitin E3 ligase SIAH2 by introducing menadione (vitamin K3), as this has been shown to stimulate cell death in human CML stem/progenitor cells and increase levels of DYRK2. The drawback to this approach is that vitamin K3 can be toxic. To remedy this, the authors suggest SIAH2 inhibitors with lower hematological toxicity, evaluating the safety of that inhibition, and developing alternatives to activating DYRK2 in CML LSCs. In other words, stabilize or increase DYRK2 levels to inhibit LSCs.

Having set out to better their understanding of LSC renewal for new inroads to treatment-free survival and relapse prevention, Lacarozza and colleagues did just that. They identified the DYRK2 checkpoint in LSC/progenitor cell survival and self-renewal, showing there are 2 ways to increase its levels: (1) remove the Klf4 gene or (2) inhibit the ubiquitin ligase SIAH2 pharmacologically.

At present, they continue to search for ways to accomplish this that will not harm patients with CML, who today must take TKIs for life. We envision that targeting the bulk of leukemia with tyrosine kinase inhibitors plus a new drug that targets the stem cells might be a future strategy for patients to reach drug-free remission.

Reference

Park CS, Lewis A, Chen T, et al. KLF4 represses DYRK2 inhibition of self-renewal and survival through c-Myc and p53 in leukemia stem/progenitor cells [published online September 12, 2019]. Blood. doi: 10.1182/blood.2018875922.

Read the original:
Treatment-free Remission at Heart of New CML Study - AJMC.com Managed Markets Network

Read More...

Page 833«..1020..832833834835..840850..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick